<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92568">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02105454</url>
  </required_header>
  <id_info>
    <org_study_id>5172-048</org_study_id>
    <secondary_id>2013-004213-41</secondary_id>
    <nct_id>NCT02105454</nct_id>
  </id_info>
  <brief_title>Study of MK-5172 + MK-8742 + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)</brief_title>
  <official_title>A Phase II Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects With Chronic Hepatitis C Virus Infection Who Failed Prior Direct Acting Antiviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, participants with hepatitis C virus (HCV) genotype 1 (GT1) who failed prior
      direct-acting antiviral (DAA) therapy will receive MK-5172 + MK-8742 + Ribavirin (RBV) to
      evaluate sustained virologic response (SVR) using this drug combination.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of participants achieving SVR at 12 weeks after the end of all study therapy (SVR12)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing adverse events</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants discontinuing study drug due to adverse events</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving SVR12 by prior DAA therapy</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive MK-5172, 100 mg tablet, orally once per day (QD) for 12 weeks; MK-8742, 50 mg tablet, orally, QD for 12 weeks; RBV capsules, 800-1400 mg weight-based dose, orally, twice per day (BID) for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-5172</intervention_name>
    <arm_group_label>All participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8742</intervention_name>
    <arm_group_label>All participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <arm_group_label>All participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Documented chronic HCV GT1 infection (with no evidence of non-typable or mixed
             genotype)

          -  Absence of cirrhosis, or cirrhosis with these criteria: METAVIR F4, or Fibroscan with
             result &gt;12.5 kPa, or FibroSure® (Fibrotest®) score of &gt;0.75 + aspartate
             aminotransferase (AST): platelet ratio index (APRI) of &gt;2- Prior regimen containing
             an approved DAA (boceprevir, telaprevir, simeprevir, or sofosbuvir), pegylated
             interferon, and/or ribavirin

          -  Participants of reproductive potential must agree to remain truly abstinent or use
             (or have their partner use) 2 acceptable methods of birth control from at least 2
             weeks prior to Day 1 and continue until at least 6 months after last dose of study
             drug, or longer if dictated by local regulations

        Exclusion criteria:

          -  Received any HCV regimen containing a DAA with the exception of boceprevir,
             telaprevir, simeprevir, or sofosbuvir in combination with pegylated interferon and/or
             ribavirin

          -  Evidence of decompensated liver disease or cirrhosis

          -  Co-infected with hepatitis B virus or human immunodeficiency virus (HIV)

          -  History of malignancy &lt;=5 years prior to signing informed consent except for
             adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
             or carcinoma in situ; or under evaluation for other active or suspected malignancy

          -  Evidence of hepatocellular carcinoma (HCC) or under evaluation for HCC

          -  Currently participating or has participated in a study with an investigational
             compound within 30 days of signing informed consent and is not willing to refrain
             from participating in another such study during the course of this study

          -  Clinically-relevant drug or alcohol abuse within 12 months of screening

          -  Pregnant, breast-feeding, or expecting to conceive or donate eggs or sperm from at
             least 2 weeks prior to Day 1 and continue throughout treatment and follow up,  or
             longer if dictated by local regulations

          -  Male participant whose female partner (s) is/are pregnant

          -  Organ transplants (including hematopoietic stem cell transplants) other than cornea
             and hair

          -  Poor venous access

          -  History of gastric surgery (e.g., stapling, bypass) or history of malabsorption
             disorders (e.g., celiac sprue disease)

          -  Hemoglobinopathy, including, but not limited to, thalassemia major

          -  Any medical condition requiring, or likely to require, chronic systemic
             administration of corticosteroids during the course of the trial

          -  Evidence or history of chronic hepatitis not caused by HCV, including but not limited
             to nonalcoholic steatohepatitis (NASH), drug-induced hepatitis, and autoimmune
             hepatitis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0004)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0009)</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0005)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>April 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
